The FDA approved Wegovy HD—a new 7.2 mg dose of semaglutide—on March 19, 2026, making it the highest-dose injectable semaglutide available for weight management. The approval, completed in just 54 days under the Commissioner’s National Priority Voucher pilot program, was supported by the STEP UP trial, which demonstrated 18.7% mean weight loss at 72 weeks. Novo Nordisk is targeting pharmacy availability in April 2026.

Why Wegovy HD Matters for the Semaglutide Landscape

The original Wegovy tops out at 2.4 mg weekly. Wegovy HD triples that ceiling to 7.2 mg, and the clinical data show the additional dose translates to meaningfully greater weight reduction.

In the STEP UP trial—a randomized, double-blind, placebo-controlled study of 1,407 adults with obesity or overweight with at least one weight-related comorbidity—participants receiving semaglutide 7.2 mg lost an average of 18.7% of their body weight at 72 weeks, compared with 3.9% in the placebo group. Nearly one in three participants (31.2%) achieved at least 25% body weight reduction, a threshold that approaches the efficacy range previously associated only with tirzepatide and surgical intervention.

For context, the original Wegovy 2.4 mg produced approximately 15% weight loss in the STEP 1 trial. Wegovy HD narrows the efficacy gap between semaglutide and tirzepatide, which achieved roughly 20% weight loss in the SURMOUNT-1 trial at the 15 mg dose.

The Accelerated Approval Path

Wegovy HD is the fourth product approved under the FDA’s National Priority Voucher pilot program, which provides an expedited review pathway for designated priority therapies. The application was accepted and approved within 54 days—a remarkably compressed timeline that reflects both the agency’s familiarity with semaglutide’s safety profile and the current political priority placed on obesity therapeutics.

The approval covers the same indication as the original Wegovy: chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. It is administered as a once-weekly subcutaneous injection using a single-dose pen.

A New Side Effect Signal: Altered Skin Sensation

The STEP UP safety data introduced a side effect not prominently associated with lower semaglutide doses: altered skin sensation, described as sensitivity, pain, or burning. The FDA noted that these reports “occurred more frequently at the higher Wegovy dosage than lower dosages” and “generally resolved on its own or with dose reduction.”

This finding is notable in the context of a parallel signal from a different incretin therapy. In the Phase III TRIUMPH-4 trial of retatrutide—Eli Lilly’s triple-agonist (GLP-1/GIP/glucagon)—dysesthesia (abnormal sensation of touch) occurred in 20.9% of participants at the 12 mg dose, compared with just 0.7% on placebo. That signal was also dose-dependent and did not appear in earlier, lower-dose trials.

Whether higher-dose incretin therapies share a class-level sensory side effect is an open question. The mechanisms are unclear—both compounds activate GLP-1 receptors, and both show the signal primarily at their highest tested doses. This is an area worth monitoring as additional TRIUMPH program readouts (seven more expected in 2026) and real-world Wegovy HD data accumulate.

The more common adverse reactions remained gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain—consistent with the known semaglutide profile.

What This Means for Peptidings Readers

If you are currently on Wegovy 2.4 mg and have plateaued: Wegovy HD offers a potential next step within the same molecule, without switching to a different drug class. The STEP UP data suggest meaningful additional weight loss from the higher dose.

If you are comparing semaglutide and tirzepatide: The efficacy gap has narrowed. Wegovy HD’s 18.7% at 72 weeks is closer to tirzepatide’s ~20% than the original Wegovy’s ~15%, though head-to-head data at these specific doses do not yet exist. Peptidings’ semaglutide compound article and tirzepatide comparison content cover the full evidence picture.

If you are concerned about side effects: The altered skin sensation signal is worth discussing with your prescriber, particularly if you have a history of neuropathy or sensory conditions. The effect appears dose-dependent and generally self-resolving.

On cost and access: Wegovy HD enters a market where GLP-1 insurance coverage is actively contracting—12 million people lost Wegovy coverage and 12 million lost Zepbound coverage from 2025 to 2026, according to GoodRx data reported by NPR. The federal Most-Favored-Nation pricing platform offers semaglutide agents at $350/month for self-pay patients and $245/month through Medicare/Medicaid. Novo Nordisk has not yet announced Wegovy HD-specific pricing separate from the existing Wegovy price structure.

References

1. FDA. “FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide.” March 19, 2026. FDA.gov
2. Novo Nordisk. “FDA approves Novo Nordisk’s new Wegovy HD injection.” Press release, March 19, 2026. PR Newswire
3. “Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process.” AJMC, March 2026. AJMC
4. Eli Lilly. “Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” December 2025. Eli Lilly Investor Relations
5. “Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges.” BioSpace, December 2025. BioSpace
6. NPR. “Patients struggle to pay for obesity drugs as insurance coverage slips.” April 22, 2026. NPR